Evidence map›Paper›PMID 42688272›Full record

ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2026

[Effect of Cancer Antigen-125 Elimination Rate Constant K and

Yuebo Li, Mengru Li, Xiuyun Zhang, Hanjie Xu, Jie Li, Hanyuan Liu, Cheng Peng

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuebo Li（ 230001）Department of Obstetrics and Gynecology, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.ORCID 0009-0004-9176-3106
Mengru Li（ 230001）Department of Obstetrics and Gynecology, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.
Xiuyun Zhang（ 230001）Department of Obstetrics and Gynecology, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.
Hanjie Xu（ 230001）Department of Obstetrics and Gynecology, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.
Jie Li（ 230001）Department of Obstetrics and Gynecology, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.
Hanyuan Liu（ 230001）Department of Obstetrics and Gynecology, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.
Cheng Peng（ 230001）Department of Obstetrics and Gynecology, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.ORCID 0000-0001-5758-0905

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the predictive value of the cancer antigen-125 elimination rate constant K (KELIM) for treatment response and prognosis in patients with advanced high-grade serous ovarian cancer (HGSOC) undergoing neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS), and to analyze the combined prognostic significance of KELIM and the mutation status of breast cancer susceptibility gene ( Methods: A total of 106 patients with advanced HGSOC who had undergone NACT-IDS were retrospectively enrolled. The KELIM values during neoadjuvant chemotherapy were calculated, and patients were divided into high- and low-KELIM groups using a cutoff value of 1.0. Clinicopathological characteristics, R0 resection rates, and platinum sensitivity rates were compared between the two groups. Logistic regression analysis was performed to identify predictive factors for R0 resection, while Kaplan-Meier survival analysis and Cox proportional hazards regression were performed to evaluate factors associated with progression-free survival (PFS). Furthermore, the patients were stratified according to both KELIM and Results: The R0 resection rate was higher in the KELIM ≥ 1 group than in the KELIM < 1 group (77.1% vs 55.2%), and the difference was statistically significant ( Conclusion: KELIM is an effective dynamic biomarker for predicting surgical outcomes and PFS in patients undergoing NACT-IDS. Combined stratification by KELIM and

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCA-125 AntigenCystadenocarcinoma, SerousCytoreduction Surgical ProceduresOvarian NeoplasmsAgedBRCA1 ProteinBRCA2 ProteinChemotherapy, AdjuvantDrug Resistance, NeoplasmFemaleHumansKaplan-Meier EstimateMiddle AgedMutationNeoadjuvant TherapyBRCA1 ProteinBRCA2 ProteinCA-125 AntigenBRCA geneCancer antigen-125 elimination rate constant KHigh-grade serous ovarian cancerInterval debulking surgeryNeoadjuvant chemotherapy

Identifiers

PMID42688272
PMCPMC13534518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.